Follow-up of 28 HCMV seropositive renal-transplant recipients:: comparison of clinical, biological and virological parameters in the groups of treated versus untreated infected patients

被引:6
作者
Kamar, N
Mengelle, C [1 ]
Yahyaoui, S
Sandres-Sauné, B
Durand, D
Izopet, J
Rostaing, L
机构
[1] CHU Toulouse, Unite Transplantat Organes, Hop Rangeil, Toulouse, France
[2] CHU Toulouse, Virol Lab, Hop Purpan, TSA 40031, F-31059 Toulouse, France
关键词
HCMV seropositive renal-transplant recipients; pre-emptive treatment; quantitative real-time PCR; clinical and biological abnormalities; outcome;
D O I
10.1016/j.jcv.2004.09.028
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: A pre-emptive strategy for prevention of Human Cytomegalovirus (HCMV) disease depends oil accurate detection of HCMV infection and clinical and/or biological abnormalities. Objectives: The aim of our study was to evaluate a therapeutic strategy based oil the presence of either minimal clinical and/or biological symptoms or high HCMV viral load assessed by quantitative real-time PCR from whole blood as previously described. Study design: Between June 2002 and July 2003, 70 HCMV seropositive patients underwent a renal transplantation. Virological monitoring was performed every 2 weeks until day 90 then every 3-4 weeks until day 180. Biochemical and haematological parameters were also prospectively monitored. Results: Twenty-eight patients (40%) showed at least one positive HCMV DNA in whole blood. Based on the following criteria: HCMV viral load greater than 4 log(10)/ml, or the persistence of a HCMV DNAemia in two consecutive blood samples, or fever, or leucopenia or neutropenia, or increase in alanine aminotransferase level, 14 of the 28 patients received IV ganciclovir as a pre-emptive treatment. Immunosuppressive therapy and demographical data were comparable in both groups. As far as virological, haematological and biochemical parameters are concerned, no statistical significant difference was observed between treated and untreated patients. Moreover no adverse Outcome was observed among untreated patients always having a HCMV viral load below 4 log(10)/ml. Conclusions: This study reinforces the need of monitoring of HCMV seropositive renal-transplant recipients based on HCMV diagnosis and quantification by real-time PCR. The results showed that HCMV viraemic patients may benefit of absence of antiviral treatment when they have a low viral load (below 4 log(10)/ml) and absence of clinical and/or biological abnormalities. Further studies are required now to validate the threshold value at which we should begin pre-emptive therapy. (c) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:35 / 42
页数:8
相关论文
共 31 条
[1]   Use of molecular assays in diagnosis and monitoring of cytomegalovirus disease following renal transplantation [J].
Aitken, C ;
Barrett-Muir, W ;
Millar, C ;
Templeton, K ;
Thomas, J ;
Sheridan, F ;
Jeffries, D ;
Yaqoob, M ;
Breuer, J .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (09) :2804-2807
[2]  
[Anonymous], AM J TRANSPLANTAT S5
[3]   Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation - Comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture [J].
Boeckh, M ;
GallezHawkins, GM ;
Myerson, D ;
Zaia, JA ;
Bowden, RA .
TRANSPLANTATION, 1997, 64 (01) :108-113
[4]   Distinguishing cytomegalovirus (CMV) infection and disease with CMV nucleic acid assays [J].
Caliendo, AM ;
St George, K ;
Allega, J ;
Bullotta, AC ;
Gilbane, L ;
Rinaldo, CR .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (05) :1581-1586
[5]   Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation [J].
Cope, AV ;
Sabin, C ;
Burroughs, A ;
Rolles, K ;
Griffiths, PD ;
Emery, VC .
JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (06) :1484-1490
[6]   Quantification of human cytomegalovirus DNA by real-time PCR [J].
Gault, E ;
Michel, Y ;
Dehée, A ;
Belabani, C ;
Nicolas, JC ;
Garbarg-Chenon, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (02) :772-775
[7]  
GOUARIN SVA, 2003, J CLIN VIROL
[8]   Evaluation of CMV viral load using Taqman™ CMV quantitative PCR and comparison with CMV antigenemia in heart and lung transplant recipients [J].
Guiver, M ;
Fox, AJ ;
Mutton, K ;
Mogulkoc, N ;
Egan, J .
TRANSPLANTATION, 2001, 71 (11) :1609-1615
[9]  
Hassan-Walker AF, 1999, J MED VIROL, V58, P182, DOI 10.1002/(SICI)1096-9071(199906)58:2&lt
[10]  
182::AID-JMV14&gt